SCHEMBL22445033

SCHEMBL22445033

COC(=O)c1ccccc1NC(=O)c1ccc(Br)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.74
▸ CYP1A2 P05177 1/20 0.74
▸ CYP2D6 P10635 1/20 0.74
▸ CYP2C19 P33261 1/20 0.74
▸ APOBEC3A P31941 1/20 0.68
▸ APOBEC3G Q9HC16 1/20 0.68
▸ MAPK1 P28482 2/20 0.67
▸ HPGD P15428 3/20 0.65
▸ MAPK10 P53779 1/20 0.65
▸ KDM4E B2RXH2 7/20 0.64
▸ ALDH1A1 P00352 6/20 0.64
▸ RAB9A P51151 3/20 0.64
▸ ELANE P08246 1/20 0.64
▸ PRTN3 P24158 1/20 0.64
▸ HSD17B10 Q99714 2/20 0.63
▸ MAPT P10636 6/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ KMT2A Q03164 6/20 0.60
▸ MEN1 O00255 3/20 0.60
▸ POLB P06746 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2290505 0.88 KDM4E (0.67) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL11665959 0.87 TSHR (0.77) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL4203434 0.86 TSHR (0.76) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL9339256 0.86 TSHR (0.76) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL10325817 0.86 KDM4E (0.76) TSHRCYP1A2CYP2C19MAPK1HPGD
SCHEMBL4459274 0.85 TSHR (1.00) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL11045073 0.85 F10 (0.77) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL29378181 0.85 TSHR (1.00) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL9337435 0.84 TSHR (0.68) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A
SCHEMBL6242064 0.84 TSHR (0.80) TSHRCYP1A2CYP2D6CYP2C19APOBEC3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122194-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS THE GENERAL HOSPITAL CORPORATION 2025-04-17 — — US disclosed
US-12187722-B2 Small molecule inhibitors of TEAD transcription factors THE GENERAL HOSPITAL CORPORATION (US) 2025-01-07 — — US disclosed
US-20230113085-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS THE GENERAL HOSPITAL CORPORATION 2023-04-13 — — US disclosed
EP-3937943-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS The General Hospital Corporation (US) 2022-01-19 — — EP disclosed
CN-113811300-A Novel small molecule inhibitors of TEAD transcription factor 总医院公司 2021-12-17 — — CN disclosed
WO-2020190774-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS THE GENERAL HOSPITAL CORPORATION (US) 2020-09-24 — — WO disclosed
WO-2020190774-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS THE GENERAL HOSPITAL CORPORATION (US) 2020-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187722-B2 Small molecule inhibitors of TEAD transcription factors TEAD1, TEAD2, TEAD3 TSHR 2808/4885CYP1A2 4382/4885CYP2D6 4626/4885
US-20250122194-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS TEAD1, TEAD2, TEAD3 TSHR 2931/4885CYP1A2 4522/4885CYP2D6 4682/4885
US-20230113085-A1 NOVEL SMALL MOLECULE INHIBITORS OF TEAD TRANSCRIPTION FACTORS TEAD1, TEAD2, TEAD3 TSHR 2931/4885CYP1A2 4522/4885CYP2D6 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback